Patents Assigned to North Shore-Long Island Jewish Research Institute
  • Patent number: 7060504
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 13, 2006
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Patent number: 6994991
    Abstract: The present invention provides genomic loci which are hypermethylated and differentially expressed in drug resistant cells compared to non-drug resistant cells. These genomic loci are homologous to the rab6 locus but map to a different chromosomal position. The present invention also provides nucleic acids isolated from these genomic loci by Methyl-Differential Display (MDD) methods, including genomic DNAs and cDNAs. The present nucleic acids are useful as probes for detecting mutations and the methylation patterns of the newly identified genomic loci, and of homologous nucleic acids. Nucleic acids of the present invention are also useful for detecting expression of mRNA from herein identified genes, for measuring expression of those and homologous genes sequences, and for determining suitability of therapeutic treatment. The disclosed nucleic acids and their homologs are useful for inhibition of multiple drug resistance.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: February 7, 2006
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventors: Hao-Peng Xu Duffy, Ji-dong Shan, Li-ming Yuan, Daniel Budman, Anthony Calabro
  • Publication number: 20050282906
    Abstract: Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount of cholinergic agonist or acetylcholinesterase inhibitor to the subject.
    Type: Application
    Filed: March 24, 2005
    Publication date: December 22, 2005
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin Tracey, Carol Amella, Christopher Czura
  • Publication number: 20050245609
    Abstract: This invention is directed to a method of using a therapeutic composition comprising an ester of an alpha-ketoalkanoic acid for the treatment of cytokine-mediated inflammatory conditions. The cytokine-mediated inflammatory conditions are mediated by, for example, Tumor Necrosis Factor (TNF), interleukin-1? (IL-1?)) or High Mobility Group B-1 (HMGB-1) mediator of inflammation. Exemplary cytokine-mediated inflammatory conditions include, but are not limited to, rheumatoid spondylitis, osteoarthritis, gouty arthritis, endotoxic shock, cerebral malaria, silicosis, pulmonary sarcoidosis, bone resorption disease, graft versus host disease, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), Crohn's disease, rheumatoid arthritis, cachexia and septic shock.
    Type: Application
    Filed: March 31, 2005
    Publication date: November 3, 2005
    Applicants: University of Pittsburgh of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research Institute
    Inventors: Mitchell Fink, Luis Ulloa, Kevin Tracey, Russell Delude
  • Publication number: 20050222123
    Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.
    Type: Application
    Filed: January 27, 2005
    Publication date: October 6, 2005
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin Tracey, Valentin Pavlov
  • Patent number: 6943190
    Abstract: This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1? (IL-1?)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: September 13, 2005
    Assignees: University of Pittsburgh-of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research Institute
    Inventors: Mitchell P. Fink, Luis Ulloa, Kevin J. Tracey, Russell L. Delude
  • Publication number: 20050137218
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.
    Type: Application
    Filed: September 30, 2004
    Publication date: June 23, 2005
    Applicant: North Shore Long-Island Jewish Research Institute
    Inventors: Kevin Tracey, Hong Wang
  • Publication number: 20050125044
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Application
    Filed: November 17, 2004
    Publication date: June 9, 2005
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventor: Kevin Tracey
  • Patent number: 6838471
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: January 4, 2005
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventor: Kevin J. Tracey
  • Patent number: 6833244
    Abstract: The present invention provides a method, oligonucleotide probes and primers, and assay kits for diagnosing an individual as having hypospermatogenesis associated infertility that involves demonstrating in the individual the presence or absence of a variant form of a gene in exons 6, 7, 8 or 9 of the L-VDCC &agr;1c transcript.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: December 21, 2004
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventors: Susan Benoff, Ian R. Hurley, Robert G. Pergolizzi, Leslie Goodwin
  • Publication number: 20040204355
    Abstract: Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an &agr;7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an &agr;7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an &agr;7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell.
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Hong Wang
  • Publication number: 20040120953
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: November 21, 2003
    Publication date: June 24, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20040110833
    Abstract: This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1&bgr; (IL-1&bgr;)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation.
    Type: Application
    Filed: September 15, 2003
    Publication date: June 10, 2004
    Applicants: University of Pittsburgh of the Commonwealth System of Higher Education, North Shore-Long Island Jewish Research Institute
    Inventors: Mitchell P. Fink, Luis Ulloa, Kevin J. Tracey
  • Patent number: 6747004
    Abstract: The present invention provides a method of inducing growth or enhancing survival of nervous tissue comprising contacting the nervous tissue with an amount of ebaf effective to induce the growth or enhance the survival of the nervous tissue. The present invention also provides a method for treating a subject having damaged or degenerated nervous tissue comprising administering to the subject an amount of ebaf effective to treat the damaged or degenerated nervous tissue in the subject. The present invention further provides a method for treating a neurodegenerative disease in a subject comprising administering an amount of ebaf effective to treat the neurodegenerative disease. The present invention still further provides a method for preventing the onset or reducing the severity of damaged or degenerated nervous tissue in a subject comprising administering an amount of ebaf effective to prevent the onset or reduce the severity of the damaged or degenerated nervous tissue.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: June 8, 2004
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventor: Siamak Tabibzadeh
  • Publication number: 20040053841
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Application
    Filed: June 6, 2003
    Publication date: March 18, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Huan Yang
  • Publication number: 20040048795
    Abstract: Methods for inhibiting pro-inflammatory cytokine release or inflammation in a vertebrate are provided. The methods comprise activating a brain muscarinic receptor of the vertebrate, or directly stimulating a vagus nerve pathway in the brain of the vertebrate. Also provided are methods for conditioning a vertebrate to inhibit the release of a pro-inflammatory cytokine or reduce inflammation in the vertebrate upon experiencing a sensory stimulus. The methods comprise (a) activating a muscarinic brain receptor or directly stimulating the vagus nerve pathway in the brain of the vertebrate and providing the sensory stimulus to the vertebrate within a time period sufficient to create an association between the stimulus and the activation of the brain muscarinic receptor; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the inflammation to be reduced by the sensory stimulus alone.
    Type: Application
    Filed: February 26, 2003
    Publication date: March 11, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Svetlana M. Ivanova, Kevin J. Tracey
  • Publication number: 20040038857
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Application
    Filed: May 28, 2003
    Publication date: February 26, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventor: Kevin J. Tracey
  • Publication number: 20040005316
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMG A box, and an antibody preparation that specifically binds to a vertebrate HMG B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: June 6, 2003
    Publication date: January 8, 2004
    Applicant: North Shore-Long Island Jewish Research Institute
    Inventors: Kevin J. Tracey, Huan Yang
  • Patent number: 6649588
    Abstract: The present invention provides a method for inhibiting activity of TGF-&bgr;, comprising contacting tissue expressing TGF-&bgr; with an amount of ebaf or an ebaf analogue. The present invention further provides a method for treating a condition associated with overactivity of TGF-&bgr;, particularly fibrosis, a defect in cell proliferation, or a coagulation defect. The present invention also provides a method for inhibiting activity of TGF-&bgr;, comprising contacting tissue expressing TGF-&bgr; with a modulator of ebaf expression, or a modulator of expression of an ebaf analogue. The present invention is further directed to a method for treating fibrosis in a subject in need of treatment, comprising administering to the subject an amount of ebaf or an ebaf analogue effective to treat the fibrosis.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: November 18, 2003
    Assignee: North Shore - Long Island Jewish Research Institute
    Inventors: Siamak Tabibzadeh, James M. Mason
  • Patent number: 6617434
    Abstract: The present invention provides Methyl- (or Mutant-) Differential Display (MDD) methods and nucleic acid probes for detecting mutations and the methylation patterns of nucleic acids. Regions of the genome are differentially methylated or mutated in different cell types, including cancerous cell types. The TSP50 gene is thereby identified and found to be differentially expressed in breast cancer cells. The present invention provides methods and compositions for identifying aberrant expression of the TSP50 gene and of tsp50 protein. Antibodies of the present invention can be used for diagnosis and treatment of diseases characterized by aberrant tsp50 expression.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: September 9, 2003
    Assignee: North Shore Long Island Jewish Research Institute
    Inventor: Hao-Peng Xu Duffy